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Autologous hematopoietic cell transplantation (AHCT) in
the 1990s and the advent of “novel” therapy, such as immune
modulators and proteasome inhibitors, in the 2000s have led
to impressive gains in the treatment of multiple myeloma
(MM) [1,2]. In the prenovel drug era, the therapy paradigm
composed of induction followed by planned AHCT in eligible
patients, denoted as “upfront” or early AHCT, aimed at
achieving a deeper disease response and longer survival.
With modern induction therapies incorporating novel drugs,
the timing and need for AHCT is increasingly debated
because an additional survival beneﬁt for early AHCT has not
been established with modern induction regimens. Routine
post-transplant consolidation and maintenance are new
trends in AHCT-based treatment of MM. Second-generation
immune modulators and proteasome inhibitors, sensitive
prognostic schema, and disease-monitoring techniques are
also changing the treatment landscape. This session at the
tandem BMT meetings explores the relevance and future of
early AHCT in MM, the role of consolidation/maintenance
post-transplant, and new drug development.EARLY AUTOLOGOUS TRANSPLANTATION FOR
MYELOMA: WHAT DOES THE FUTURE HOLD?
Parameswaran N. HariBENEFITS OF NEWER INDUCTION REGIMENS
Novel drug induction regimens have unseated prior
conventional chemotherapy against which AHCT was proven
to be superior in multiple randomized studies. Among U.S.
AHCT recipients reported to the Center for International
Blood and Marrow Transplant Research in 2010, 93% had
received novel agent induction in the form of lenalidomide
alone (16%) or bortezomib alone (31%) or both (46%). Table 1
compares the reported complete or very good partial
response (CR/VGPR) rates after conventional chemotherapy
versus newer induction regimens in randomized trials. Taken
together, these data suggest that based on current induction
practice, 35% to 60% of current AHCT recipients could be
expected to be already in a VGPR or better response states
before transplant. These are similar or higher than the
CR/VGPR rates after AHCT following conventional induction.
Table 1 also suggests a response augmentation effect (of
about 20% in overall CR/VGPR) after AHCT irrespective ofFinancial disclosure: See Acknowledgments on page S24.
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rates for a large proportion of newly diagnosed patients is
from a modern three-drug induction regimen followed by
early AHCT. Similarly, the median progression-free survival
(PFS) rate with the best induction regimens and AHCT (fol-
lowed by maintenance) is in the >50 month range. Notably,
the AHCT option was mandatory and not a randomization
arm in these trials, thus preventing an analysis of its relative
value in the overall scheme. These data raise more new
questions (Table 2) concerning therapy in newly diagnosed
MM. The best pathway for using and sequencing the three
phases of modern therapy (ie, induction, intensiﬁcation, and
consolidation/maintenance) in newly diagnosed MM
patients has not been worked out in randomized trials and
is a matter of controversy. Fundamentally, the debate
surrounds the value of attempting to effect deeper responses
(when overall survival [OS] beneﬁt is unproven) at the
potential cost of additional therapy, toxicity, and quality of
life decrement [3].DEPTH OF RESPONSE
Given the increasing therapeutic options at relapse and
a long and variable clinical course even after relapse,
mortality has become (fortunately) an elusive late endpoint
in modern-day induction and AHCT trials. Most trials in
newly diagnosed patients use CR/VGPR rates and PFS as
surrogate efﬁcacy endpoints for OS. Notably, even in the era
before novel drug induction, randomized early AHCT versus
conventional therapy trials and a meta-analysis suggested
a PFS beneﬁt (in six of seven trials) or higher response rate (in
all trials) for AHCT without a consistent OS beneﬁt.
Higher CR rates are a prerequisite for eventual cure of
MM, and the achievement of a deep high-quality response
correlates with long-term survival [4]. A signiﬁcant propor-
tion of those in CR (35% at 11 years) may achieve a plateau in
survival [5]. However, the sustainability of CR is perhaps the
most important endpoint from a survival perspective. The
Arkansas experience suggests that a failure to achieve a CR
and especially an early loss of CR are short-term endpoints
that predict inferior survival [6]. In contrast to these data, it
has been demonstrated that control of MM even in the
longer term is possible without achieving CR/VGPR. All MM
clones are not equally aggressive, and a smoldering clinical
course without ongoing therapy is possible in many who are
only in a partial response.
It is reasonable to expect that the substantially higher CR
rates and PFS in modern approaches may prove practically
useful endpoints in conjunction with additional patient-
reported QOL data. The statistical perils of a PFS asTransplantation.
Table 1
Overview of Novel AgenteBased Induction with or without Early AHCT in Recent Trials
Novel Induction þ AHCT Studies Induction Regimen Best Response Pre-AHCT (%) Best Response Post-AHCT (%) Survival Endpoint
HOVON-50 [24]
N ¼ 556
TAD 37  VGPR 66  VGPR Median PFS: 34 mo*
Median OS: 73 mo
VAD 18  VGPR 54  VGPR Median PFS: 25 mo







Median PFS: 36 mo*





Median PFS: 30 mo

















TD 14  CR 37  CR Median PFS: 28 mo
VTD 35  CR 52  CR Median PFS: 56 mo*
VBMCP/
VBAD/B
21  CR 49  CR Median PFS: 35 mo
HOVON65 GMMG HD4 [28]
N ¼ 827
PAD 42  VGPR 62  VGPR Median PFS: 35 mo*
VAD 14  VGPR 36  VGPR Median PFS: 28 mo
IFM 2007-02 [29]
N ¼ 199
Vel/Dex 36  VGPR 58  VGPR Median PFS: 30 mo
VTD 49  VGPR 74  VGPR Median PFS: 26 mo
Studies Not Specifying AHCT after Induction Best Response at Four Cycles
of Induction (%)
Best Response to Ongoing
Non-AHCT Therapy (%)
Comment
Rajkumar et al. [12] (post hoc
subgroup analysis)
N ¼ 445
Len/Dex 33% > VGPR in AHCT group
39% > VGPR in continuing
therapy group
NA
57% > VGPR in continuing
therapy group
3-yr OS: 92% for AHCT
(PFS not available)
3-yr OS: 79% for continuing
therapy group
Richardson et al. [30]
N ¼ 66
RVD 11% > VGPR;
57% > VGPRepre-AHCT
67% > VGPR 18-mo PFS/OS: 75% and 97%
Evolution [31]
N ¼ 140
CVD-mod 41% > VGPR 53% > VGPR 1-yr PFS: 100% overall
RVD 32% > VGPR 51% > VGPR 1-yr PFS: 83%
CVRD 33% > VGPR 58% > VGPR 1-yr PFS: 86%
Jakubowiak et al. [32]
N ¼ 53
CarfRD 44% > nCR 83% > VGPR 2-yr PFS:-92%
VAD indicates vincristine/adriamycin and dexamethasone; TAD, thalidomide/adriamycin and dexamethasone; T, thalidomide; VBMCP, vincristine-BCNU-
melphalan-cyclophosphamide-prednisone; VBAD, vincristine-BCNU-adriamycin-dexamethasone; D or Dex, dexamethasone; Len or R, lenalidomide; Vel or V,
bortezomib; C, cyclophosphamide; Carf, carﬁlzomib; GIMEMA, Gruppo Italiano Malattie Ematologiche dell’Adulto; HOVON, Stiching Hemato-Oncologie voor
Volwassenen Nederland, Dutch-Belgian Cooperative Trial Group for Hematology Oncology; GMMG, German-Speaking MyelomaMulti-center Group; PETHEMA,
Programa para el Estudio y la Terapéutica de las Hemopatías Malignas; GEM, Grupo Español de Mieloma.
* P < .05.
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where long survival is expected after progression, PFS
correlates very poorly with OS [7]. With the increasing
availability of effective newer drugs for relapsed MM, the
postprogression survival after AHCT has improved dramati-
cally with concomitant decline in the ability of upfront
treatment trials to show OS beneﬁt.Table 2
Important Questions in the Modern Era of Autologous Transplantation
for MM
Is AHCT the best method of intensiﬁcation after induction? In terms of
PFS, CR rates, QOL?
How important is the goal of CR/VGPR at the individual patient level?
Is there an adequate surrogate endpoint(s) for survival beneﬁt? CR rate?
stringent CR (sCR) rate? Sustained CR rate?
Is there additional beneﬁt to AHCT in patients who have already
achieved VGPR/CR/sCR from induction?
Can similar overall outcomes be achieved with early versus delayed
AHCT after modern induction?
If early AHCT is abandoned, when should hematopoietic cells be
harvested?
What should the type and duration of induction therapy be in the
absence of early AHCT?
Are the beneﬁts of early AHCT similar in patients irrespective of age?
What are the pharmacoeconomic implications of the various treatment
sequencing options?
What are the consequences of nonperformance of a delayed AHCT due
to refractory relapse or worsening age and performance status?
Are there speciﬁc risk groups where AHCT is essential? Or avoidable?Biologic Basis for Early Intense Therapy
MM is now recognized as a heterogeneous multiclonally
evolving disease with independent clones that compete for
dominance over time [8]. Clonal dynamics in MM suggest
that some patients harbor stable myeloma genomes over
time, whereas about one third display a pattern of linear
clonal evolution. Higher risk patients have baseline clonal
heterogeneity and genomic instability. Nonecross-resistant
multiagent therapy aimed at inducing deep remissions and
sustained over time may thus be a strategy for targeting the
greater clonal heterogeneity and evolution in a signiﬁcant
fraction of patients. Investigators in Arkansas have pioneered
this approach in their total therapy programwhere novel and
conventional agents are used before and after AHCT. The
philosophy of induction and transplant followed by consol-
idation/maintenance (Table 3) in most current trials are
modiﬁcations of this strategy.
IS THERE A BENEFIT FOR INDIVIDUAL PATIENTS
ALREADY IN CR AFTER INDUCTION?
Minimal Residual Disease after CR
Current electrophoresis-based response deﬁnitions are
imperfect because MM is an incurable disease with inevi-
table relapse even for those in CR. Molecular and ﬂow
cytometry techniques have demonstrated the presence of
signiﬁcant residual MM in currently deﬁned CR [9]. A
comparison of minimal residual disease after current
Table 3
Ongoing and Planned Multicenter Randomized Trials in Newly Diagnosed MM
Study Group Induction Choices PBSC Collection Intensiﬁcation Consolidation/Maintenance
BMT CTN 0702 Unspeciﬁed (any) Postinduction Single AHCT versus tandem
AHCT vs. AHCT þ RVD 
4 cycles
Lenalidomide for all patients
DFCI-IFM RVD After 3 cycles AHCT vs. RVD R
EMN02 CVD After 3 cycles; with
cyclophosphamide
AHCT single or tandem vs. VMP
consolidation
RVD consolidation þ lenalidomide
vs. lenalidomide only
GMMG-HD5 CVD vs. PAD After 3 cycles; with
cyclophosphamide and
doxorubicin
AHCT; tandem AHCT for those
not in CR after AHCT1
2 cycles of lenalidomide
consolidation, then lenalidomide




VP (BVP)  3 cycles
AHCT followed by BVP  2 cycles
D or Dex indicates dexamethasone; Len or R, lenalidomide; P or V, bortezomib; C, cyclophosphamide; A, adriamycin; BMTCTN, Blood and Marrow Transplant
Clinical Trials Network; GMMG, German-Speaking Myeloma Multi-center Group; EMN, European Myeloma Network; GEM, Grupo Español de Mieloma.
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disease is lacking at this time. Because CR is such an imper-
fect tool in MM, one needs to consider the possibility that the
consequences of CR may well vary according to myeloma
genetic subtype, how the CR was deﬁned (ﬂow cytometry,
Immune Histochemistry IHC, positron emission tomography,
free light chain etc.), and how it was achieved (using novel
agents only versus novel agents with high dose therapy). The
Blood and Marrow Transplant Clinical Trials Network 0702
trial has a companion study that uses ﬂow cytometric
minimal residual disease assays to assess the impact of
sequential multistep induction, transplant, and post-
transplant therapies. In addition to quantifying the beneﬁt
of each phase of therapy, minimal residual disease data could
potentially distinguish subgroups from among current
responders that beneﬁt (or not) from AHCT.DELAYED AHCT VERSUS EARLY AHCT IN THE NOVEL
AGENT ERA
All available randomized studies (from the prenovel drug
era) suggest that survival is similar whether AHCT is per-
formed early or in the delayed setting after relapse [10]. Early
AHCT was associated with a longer treatment-free interval
and improved QOL. In the novel drug era, randomized studies
addressing this question have limited follow-up, whereas
the QOL metrics as well as the “freedom from treatment”
paradigm are different in the era of maintenance. InTable 4
Thalidomide Consolidation/Maintenance after AHCT
Study Comparison
Attal et al. Blood 2006;108:3289-94 Thalidomide and pamidronate vs.
pamidronate vs. observationy
Barlogie et al. Blood 2008;112:
3115-21
Thalidomide vs. no thalidomide
throughout total therapy II
Lokhorst et al. Blood 2010;115:
1113-20
Thalidomide vs. interferon
Morgan et al. Blood 2012;119:7-15. Thalidomide vs. observation
Spencer et al. J Clin Oncol 2009;27:
1788-93
Thalidomide and prednisone vs.
prednisone








Stewart et al. Blood (abstract) 2010;
116:39a
Thalidomide and prednisone vs.
observation
EFS indicates event free survival; PFS, progression free survival; AHCT, autologous
* þ indicates favors maintenance; e, favors no maintenance; ND, no difference.
y Pamidronate and observation arms were combined for analysis.one of the few modern randomized reports available,
Palumbo et al. randomized patients receiving lenalidomide-
dexamethasone induction to AHCT versus melphalan-
lenalidomide-prednisone combination [11]. Although CR
rates and OS were similar, early AHCT reduced the risk of
progression by 50% and PFS at 2 years was 73% versus 54% in
favor of AHCT. A post hoc landmark analysis of the Eastern
Cooperative Oncology Group E4A03 study subjects sug-
gested that after four cycles of lenalidomide-based induc-
tion, early AHCT was associated with a higher 3-year survival
(94% versus 78%) compared with continued therapy despite
the excellent (57%) VGPR rates in the continuing therapy
group [12].
Several ongoing studies explore the question of early
versus delayed AHCT. The Intergroupe Francophone du
Myélome/Dana Farber Cancer Institute (IFM/DFCI) 2009 (NCT
01208622) study randomizes subjects after three cycles of
bortezomib-lenalidomide-dexamethasone (RVD) induction
and stem cell collection to early AHCT with RVD consolida-
tion (two cycles) or continued RVD (total of eight cycles).
Both arms receive lenalidomide maintenance for 12 months,
and subjects relapsing from the nontransplant arm are ex-
pected to receive AHCT at relapse. The European Myeloma
Network 02 study (NCT 01208766) randomizes 1500 subjects
after three cycles of bortezomib-cyclophosphamide-
dexamethasone induction to single or tandem AHCT versus
intensiﬁcation with bortezomib-melphalan-prednisone fol-
lowed by a second randomization to RVD consolidationLength of Maintenance EFS or PFS* OS*
Until progression 3-yr EFSþ 4-yr OSþ
Until progression 5-yr EFSþ 8-yr OS
Trend þ
Until progression Median EFSþ Median OS
Trend e




1 yr or until progression 3-yr PFSþ 3-yr OSþ




1 yr or until progression 2-yr PFSþ 3-yr OS
ND
Until progression 4-yr PFSþ 4-yr OS
Trend þ
hematopietic cell Transplantation; OS, overall survival.
Table 5
Lenalidomide, Bortezomib, and Zoledronate Maintenance after AHCT
Study Comparison Planned Length
of Maintenance
TTP, EFS, or PFS* OS*
McCarthy et al. N Engl J Med
2012;366:1770-81





Attal et al. N Engl J Med 2012;
366:1782-91
Lenalidomide vs. placebo after 2
mo lenalidomide consolidation
for all
Until progression Median PFS, EFS, and 4-yr PFS
þ
Median OS and 4-yr OS
ND
Sonneveld et al. J Clin Oncol
2012;30:2946-55
Bortezomib-containing








Morgan et al. Lancet 2010;
376:1989-99




Median OS for all
þ
TTP indicates time to progression; EFS, event-free survival; ND, no difference.
* þ indicates favors maintenance; e, favors no maintenance.
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stratiﬁcation strategies that should inform us of the beneﬁt
of AHCT in speciﬁc risk subgroups.
TOXICITY, MORBIDITY, AND QOL: ARE TRANSPLANTS
SAFER NOW?
The Center for International Blood and Marrow Trans-
plant Research data suggest that day 100mortality of upfront
AHCT recipients between 2009 and 2011 is 1%. Modern
better-tolerated induction regimens and advances in
supportive caremay have contributed to this lower incidence
of serious toxicity. Many institutions routinely perform
AHCT in the outpatient setting. Also in contrast to popular
perception, mortality, morbidity, and societal cost from
ongoing nontransplant therapy are not trivial. QOL and
pharmacoeconomic considerations could become major
drivers in decision making.
IS THERE AN EMERGING CONSENSUS?
In the absence of survival data and clear consensus
regarding the beneﬁts of early transplantation, the design of
ongoing trials gives us an idea of what major experts in the
ﬁeld view as equipotent alternatives. Ongoing U.S. and
European cooperative group randomized trials (Table 3) in
newly diagnosedMM patients include early peripheral blood
stem cell (PBSC) collection for eligible patients and the early
AHCToption in at least one of the arms. After PBSC collection,
for the nontransplant arm, all the trials include ongoing
novel agentebased therapy (intensiﬁcation and/or consoli-
dation) followed by a lower intensity maintenance. These
study designs suggest that most experts have embraced the
idea of induction, PBSC harvest, intensiﬁcation, and consol-
idation/maintenance. AHCT at this time remains the most
popular and established intensiﬁcation choice in the absence
of evidence to the contrary. Also, it is my belief that
population/registry-based studies with long-term survival
outcome are needed to evaluate the overall impact of
advances in each component of therapy.
CONSOLIDATION AND MAINTENANCE THERAPY AFTER
UPFRONT TRANSPLANT
Philip L. McCarthy
Because most patients experience relapse and progres-
sion of MM even after AHCT, efforts have been made toconsolidate and maintain response. This section focuses on
the role of AHCT followed by consolidation and maintenance
therapy for transplant-eligible MM patients. One of the ﬁrst
trials to consolidate and maintain response in MM patients
was published in 1986 and used nitrosoureas, anthracyclines,
alkylators, and glucocorticoids as part of induction and
consolidation/maintenance therapy without improvement
in OS [13]. The use of AHCT and the development of novel
drugs allowed new attempts to improve, consolidate, and
maintain response [1,14]. “Consolidate” is deﬁned as therapy
improving on response, and “maintenance” maintains
response.CONSOLIDATION THERAPY
Recent use of consolidation has been pioneered by
the Italian Myeloma Network (Gruppo Italiano Malattie
Ematologiche dell’Adulto) [15]. After tandem AHCT, the PFS
for bortezomib, thalidomide, and dexamethasone (VTD)
consolidation was superior to thalidomide-dexamethasone
(TD) consolidation. All patients received dexamethasone
maintenance therapy. The estimated 3-year OS rates were
90% and 88% for the VTD and TD arms, respectively. A recent
review of the Arkansas Total Therapy (TT) approach
demonstrated estimated 5-year survival rates of 57%, 65%,
68%, and 73% for TT1, TT2 without thalidomide, TT2 with
thalidomide, and TT3, respectively [16]. The investigators
favor the use of all effective anti-MM therapies upfront and
in an intensive manner to prevent relapse/progression and
improve PFS and OS.MAINTENANCE THERAPY WITH THALIDOMIDE
Maintenance therapy should be easily delivered, conve-
nient for the patient, result in modest or minimal toxicity,
and improve PFS and ideally OS when compared with
retreatment at relapse [17]. Initial maintenance trials with
melphalan, interferon-a, and glucocorticoids were limited by
toxicity and/or limited efﬁcacy [18-20].
Thalidomide was considered for maintenance because it
is an oral drug and was associated with induction responses.
Several trials have used thalidomide as consolidation/
maintenance therapy alone or with glucocorticoids until
progression or for a ﬁxed period of time after AHCT. The
results of these trials with references are summarized in
Table 4. All studies demonstrated that thalidomide improved
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to OS. The lack of consistent OS beneﬁt may be due to
effective salvage therapies that can prolong OS or the
inability to tolerate prolonged thalidomide therapy due to
toxicity for a signiﬁcant number of patients.LENALIDOMIDE MAINTENANCE
Lenalidomide was studied in two phase III, placebo-
controlled maintenance trials after AHCT: Cancer and
Leukemia Group B (CALGB) 100104 and IFM 05-02. The
results and references are given in Table 5. Both studies
demonstrated a superior time to progression, PFS, and event-
free survival. CALGB 100104 demonstrated an improved OS
for the lenalidomide arm compared with the placebo arm.
Most placebo arm patients crossed over to receive lenalido-
mide after the study was unblinded when the primary
endpoint (time to progression) had been met. On an intent-
to-treat analysis, the OS beneﬁt persisted despite the cross-
over. The IFM 05-02 study did not demonstrate an OS beneﬁt,
which could be due to induction treatment/consolidation
differences, lenalidomide consolidation for both arms, and
the use of tandem AHCT for some patients.
A two- to threefold increase was found in second primary
malignancies in both studies associated with the lenalido-
mide arm. It is uncertain as to the exact risk factors for the
development of a second primarymalignancy for patients on
the lenalidomide arm. The IFM investigators found a corre-
lation with the type of consolidation pre-AHCT, age, Inter-
national Scoring System stage, gender, and length of time of
lenalidomide maintenance (M. Attal, unpublished observa-
tion). There were no signiﬁcant pre- or post-AHCT patient
characteristics for risk of second primary malignancies in the
CALGB 100104 study except for lenalidomide maintenance.
For the CALGB 100104 study, the cumulative incidence risk
of progressive disease or death was signiﬁcantly greater
for the placebo arm when compared with the lenalidomide
arm, and the cumulative incidence risk of second primary
malignancies was signiﬁcantly greater for the lenalidomide
arm when compared with the placebo arm. The IFM 05-02
patients stopped lenalidomide maintenance, and CALGB
100104 patients without disease progression remain on
lenalidomide.BORTEZOMIB MAINTENANCE
Bortezomib was investigated in the Stiching Hemato-
Oncologie voor Volwassenen Nederland, Dutch-Belgian
Cooperative Trial Group for Hematology Oncology and
German-Speaking MyelomaMulti-center Group as part of an
induction regimen (bortezomib, doxorubicin, and dexa-
methasone) before AHCT and maintenance (every 2 weeks
for 2 years) after transplant. It was compared with vincris-
tine, doxorubicin, and dexamethasone before AHCT and
maintenance with thalidomide (daily for 2 years). PFS was
superior for patients receiving bortezomib as part of induc-
tion and maintenance, with an OS beneﬁt in multivariate
analysis for bortezomib induction and maintenance.
Zoledronate was compared with clodronate mainte-
nance until progression in the MRC Myeloma IX trial. This
study was composed of patients receiving and not receiving
AHCT as part of treatment. PFS was not signiﬁcantly
different for AHCT patients receiving zoledronate when
compared with those receiving clodronate. There was
a trend toward an improved median OS for the zoledronate
arm when compared with the clodronate arm (not reachedversus 62.5 months). Data and references are summarized
in Table 5.
FUTURE OF MAINTENANCE AND CONSOLIDATION
Long-term disease control remains an important goal of
MM treatment. Recent clinical trials have focused on
improving response as depth of response correlates with
long-term outcome for patients undergoing AHCT [9,21].
MM patients who attain ﬂow cytometric and molecular
remissions have improved long-term outcomes. All ongoing
trials (Table 3) that are investigating the role of early AHCT
versus salvage AHCT incorporate upfront maintenance. The
IFM DFCI 2009 trial has completed accrual in France and uses
1 year of lenalidomide maintenance therapy for all patients,
whereas U.S. investigators will continue lenalidomide
maintenance until progression/relapse. The ongoing Blood
and Marrow Transplant Clinical Trials Network study incor-
porates 3 years of lenalidomide maintenance therapy after
different intensiﬁcation choices. This study will help deter-
mine the role of single versus tandem AHCT versus AHCTand
consolidation therapy for newly diagnosed MM patients. The
European Myeloma Network also incorporates lenalidomide
maintenance therapy monthly for 3 weeks on and 1 week off
until disease progression following different intensiﬁcation
options.
These trials will further deﬁne which MM patients will
beneﬁt from speciﬁc treatment approaches. The incorpora-
tion of new agents into induction, consolidation, and main-
tenance approaches should result in further improvement in
PFS and OS [22]. Risk stratiﬁcationwill allow for patients and
clinicians to determine the optimal approach for individual
MM patients [23]. Prolonged treatment with induction by
novel agents, consolidation before and/or after AHCT, and
maintenance treatment have become the standard approach
to induce an undetectable/minimal residual disease remis-
sion status that will improve long-term patient outcomes.
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